TerminatedNCT00566111
Ceftriaxone in the Management of Depression in bipolarity
Medication studyAges 18–65United States
Understand this study
Who could participate?
This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- New HavenSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateSeptember 2007
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 5
- Sponsor
- Yale University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00566111
- Official title
Show the full official title
Modulation of Glutamatergic Neurotransmission in the Treatment of Bipolar Depression
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New Haven
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Yale University, a university.
Does this study involve medication?
Yes. The study involves medication, including ceftriaxone and Saline solution.
Who can participate?
This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Depression in bipolarity
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolarity type I.